Oragenics (OGEN) announced that it has regained full compliance with NYSE American’s continued listing standards and is positioning the company to focus exclusively on advancing its lead clinical program.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OGEN:
- Oragenics, Receptor.AI partner to accelerate pipeline development
- Oragenics Appoints Natasha Giordano to Board of Directors